Efficacy and safety of oral Chinese patent medicine combined with sacubitril/valsartan in the treatment of chronic heart failure:A Metaanalysis  

作　　者：TAO Shi-yi TANG Xian-wen ZHANG Lan-xin YU Lin-tong ZHANG Jin YANG Deshuang LI Ling-ling HUANG Li WU Jia-yun 

机构地区：[1]Beijing university of Chinese medicine,Beijing 100029,China [2]Shenzhen Hospital of Beijing University of Chinese Medicine,Guangdong 518000,China [3]Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100053,China [4]The First Hospital of Hebei Medical University,Hebei 050031,China [5]China-Japan Friendship Hospital,Beijing 100029,China

出　　处：《Journal of Hainan Medical University》2023年第16期52-60,共9页海南医学院学报（英文版）

基　　金：National Natural Science Foundation of China (No.81803925);National Key Research and Development Program (No.2017YFC1700102)。

摘　　要：Objective:To systematically evaluate the clinical efficacy of oral Chinese patent medicine combined with sacubitril/valsartan in treating chronic heart failure(CHF).Methods:CNKI,CSPD,CCD,CBM,PubMed,Web of Science,Cochrane Library and EMbase were retrieved to screen out randomized controlled trials Chinese patent medicine and Western medicine in treating CHF.Manual retrieval was also applied as a supplement.The Cochrane Reviewers Handbook 5.1.0 was used to evaluate the bias risk of the included studies and RevMan 5.4 software was used for Meta-analysis.Results:A total of 1301 patients enrolled in the 13 RCTs were included.According to the results of Meta-analysis,a combination of oral Chinese patent medicine and sacubitril/valsartan could further improve total effectiveness rate(RR=1.23,95%CI[1.16,1.30],P<0.001),increase 6 minutes’walk distance(MD=53.04,95%CI[33.43,72.64],P<0.001),improve left ventricular ejection fraction(MD=6.67,95%CI[5.15,8.19],P<0.001)and stroke volume(MD=7.56,95%CI[3.94,11.18],P<0.001),reduce left ventricular end-diastolic dimension(MD=-3.68,95%CI[-4.57,-2.78],P<0.001)and N terminal pro B type natriuretic peptide(MD=-434.08,95%CI[-518.95,-349.22],P<0.001)and no statistically significant difference in drug safety was found between the sacubitril/valsartan-only group and the combined treatment group(RR=0.73,95%CI[0.32,1.65],P=0.45).Conclusion:It’s indicated that a combination of traditional Chinese patent medicine and sacubitril/valsartan had a good clinical efficacy in the treatment of CHF,which had certain guiding significance for clinical practice.

关 键 词：Oral Chinese patent medicine Sacubitril/valsartan Angiotensin receptor-neprilysin inhibitor Chronic heart failure Qili Qiangxin Capsule Qishen Yiqi Pill Dengzhan Shengmai Capsule 

分 类 号：R541.6[医药卫生—心血管疾病]